Treatment for stage 2 essential thrombocythemia is highly personalized. Not every patient requires medication right away, and ...
The FDA has accepted the supplemental Biologics License Application (BLA) for ropeginterferon alfa-2b-njft (Besremi), a ...
National Comprehensive Cancer Network adds Ropeg to guidelines after Phase 3 trial shows 43% long-term patient response | ...
Explore the evolving landscape of myeloma treatment, focusing on maintenance therapies and patient experiences with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results